Ticker Launch
Sign inTry it free

SPAC · Merger completed

Forbion European Acquisition Corp.

Business combination with enGene Inc.

Forbion European Acquisition Corp. is a blank-check company (SPAC) that raised $110M in its initial public offering on Dec 13, 2021, listing on Nasdaq Global Market. It completed its business combination with enGene Inc. on Oct 31, 2023; the combined company is enGene Holdings Inc. (ENGN). UBS led the IPO. Davis Polk advised the SPAC and Kirkland & Ellis advised the underwriters on the IPO.

enGene Inc. is a clinical-stage biotechnology company developing non-viral, locally administered gene therapies based on its dually derivatized chitosan platform. The therapies are designed to be re-dosable, manufacturable at scale and integrated into community clinical practice.

Status
Merger completed
IPO date
Dec 13, 2021
IPO size
$110M
IPO exchange
Nasdaq Global Market
Target
enGene Inc. (enGene)
Announced
May 17, 2023
Closed
Oct 31, 2023
Combined company
enGene Holdings Inc. (ENGN)
IPO underwriters
UBS
SPAC counsel (IPO)
Davis Polk and Maples and Calder
Underwriters' counsel (IPO)
Kirkland & Ellis

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other deSPACs that closed in 2023